Skip to main content

Table 1 Demographics, clinical characteristics, and baseline HRQoL scores of participants randomized to four secukinumab dose groups (N = 187)

From: Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds

Demographics  
Female (n, %) 149 (79.7)
Age (mean, SD) 54.9 (10.8)
Caucasian (n, %) 137 (73.3)
Clinical assessment  
Prior use of biologics (n, %) 38 (20.3)
VAS pain intensity (mean, SD) 53.6 (20.8)
SDAI (mean, SD) 40.3 (11.9)
Patient global assessment disease activity (mean, SD) 61.6 (19.1)
Physician global assessment disease activity (mean, SD) 61.9 (14.9)
Swollen joint count (mean, SD) 11.4 (4.8)
Tender joint count (mean, SD) 14.7 (6.2)
HRQoL scales  
SF-36 Physical functioning (mean, SD) 40.5 (21.7)
SF-36 Role physical (mean, SD) 42.8 (24.3)
SF-36 Bodily pain (mean, SD) 36.1 (16.9)
SF-36 General health (mean, SD) 40.4 (16.6)
SF-36 Vitality (mean, SD) 39.0 (19.7)
SF-36 Social functioning (mean, SD) 57.2 (26.1)
SF-36 Role emotional (mean, SD) 54.1 (26.7)
SF-36 Mental health (mean, SD) 56.8 (19.4)
SF-36 Physical summary (mean, SD) 33.8 (7.5)
SF-36 Mental summary (mean, SD) 40.5 (11.0)
HAQ-DI (mean, SD) 1.49 (0.6)
FACIT-Fatigue (mean, SD) 28.3 (10.1)